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Community screening and treatment of
asymptomatic carriers of Plasmodium falciparum
with artemether-lumefantrine to reduce malaria
disease burden: a modelling and simulation
analysis
Steven E Kern1,9*, Alfred B Tiono2, Michael Makanga3, Adama Dodji Gbadoé4, Zulfiqarali Premji5, Oumar Gaye6,
Issaka Sagara7, David Ubben8, Marc Cousin9, Fiyinfolu Oladiran10, Oliver Sander9 and Bernhards Ogutu11,12
Abstract
Background: Asymptomatic carriers of Plasmodium falciparum serve as a reservoir of parasites for malaria
transmission. Identification and treatment of asymptomatic carriers within a region may reduce the parasite
reservoir and influence malaria transmission in that area.
Methods: Using computer simulation, this analysis explored the impact of community screening campaigns (CSC)
followed by systematic treatment of P. falciparum asymptomatic carriers (AC) with artemether-lumefantrine (AL) on
disease transmission. The model created by Okell et al (originally designed to explore the impact of the
introduction of treatment with artemisinin-based combination therapy on malaria endemicity) was modified to
represent CSC and treatment of AC with AL, with the addition of malaria vector seasonality. The age grouping,
relative distribution of age in a region, and degree of heterogeneity in disease transmission were maintained. The
number and frequency of CSC and their relative timing were explored in terms of their effect on malaria incidence.
A sensitivity analysis was conducted to determine the factors with the greatest impact on the model predictions.
Results: The simulation showed that the intervention that had the largest effect was performed in an area with
high endemicity (entomological inoculation rate, EIR > 200); however, the rate of infection returned to its normal
level in the subsequent year, unless the intervention was repeated. In areas with low disease burden (EIR < 10), the
reduction was sustained for over three years after a single intervention. Three CSC scheduled in close succession
(monthly intervals) at the start of the dry season had the greatest impact on the success of the intervention.
Conclusions: Community screening and treatment of asymptomatic carriers with AL may reduce malaria
transmission significantly. The initial level of disease intensity has the greatest impact on the potential magnitude
and duration of malaria reduction. When combined with other interventions (e.g. long-lasting insecticide-treated
nets, rapid diagnostic tests, prompt diagnosis and treatment, and, where appropriate, indoor residual spraying) the
effect of this intervention can be sustained for many years, and it could become a tool to accelerate the reduction
in transmission intensity to pre-elimination levels. Repeated interventions at least every other year may help to
prolong the effect. The use of an effective diagnostic tool and a highly effective ACT, such as AL, is also vital. The
modelling supports the evaluation of this approach in a prospective clinical trial to reduce the pool of infective
vectors for malaria transmission in an area with marked seasonality.
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Background
Following the publication of the Millennium Develop-
ment Goals in 2000, which called for a reversal in the
progression of malaria by 2015 [1], an increased com-
mitment to a number of treatment and prevention stra-
tegies has since yielded some highly successful results.
The number of deaths attributable to malaria has signifi-
cantly decreased in Rwanda, Ethiopia, Zanzibar, Equa-
torial Guinea, and Sao Tome and Principe [2-4], owing
to combined strategies of mass distribution of insecti-
cide-treated bed nets (ITN), an increased use of long-
lasting insecticide-treated nets (LLIN), intermittent pre-
ventive treatment in pregnancy (IPT), and widespread
adoption of artemisinin-based combination therapy
(ACT). However, additional complementary interven-
tions are still required to further accelerate the reduc-
tion in disease burden in areas that have already
implemented a number of strategies to reduce disease
transmission. The detection and treatment of asympto-
matic carriers of Plasmodium falciparum as an innova-
tive strategy for malaria control has been previously
considered [5-8] and the latest WHO Guidelines for the
Treatment of Malaria note that infectivity-reducing drug
regimens will have a useful role to play in maintaining
the reductions in disease transmission achieved through
integrated control programs [9].
The transmission of P. falciparum parasites from
humans to mosquitoes requires the presence of infec-
tious gametocytes in the human peripheral blood.
Asymptomatic carriers (AC) are individuals who har-
bour the P. falciparum asexual forms, with or without
gametocytes, but do not present clinical symptoms of
the disease. In malaria-endemic countries, a large pro-
portion of P. falciparum infections are asymptomatic or
sub-clinical. Microscopy-detected levels of asymptomatic
carriage as high as 60% have been reported [5,7,10]. AC
do not usually seek treatment for their infection, and
therefore constitute a reservoir of parasites for the
inoculation of newly-hatched mosquitoes that contri-
butes to the transmission of the disease.
Detecting and treating asymptomatic carriers would be
likely to produce benefits at both the individual level
and at the community level. Patients with asymptomatic
P. falciparum chronic infection, especially children,
experience an increased morbidity due to anaemia, and
reduced cognitive development [11]. In this situation,
the use of surveillance with community screening and
systematic treatment of asymptomatic cases becomes an
important clinical tool. In addition, work has demon-
strated the pervasive effect of malaria on a country’s
socioeconomic situation [12]. At a community-level, sys-
tematic treatment of AC could contribute to a reduced
incidence of malaria, which would bring socioeconomic
and healthcare benefits. A similar approach was pub-
lished recently [13], which used a school based interven-
tion of intermittent screening by rapid diagnostic tests
(RDT) and treatment with artemether-lumefantrine (AL)
to assess educational improvement in children. While
this approach targeted a large proportion of the suscep-
tible population, it would not decrease the disease reser-
voir present in younger children or adults.
For this intervention on AC to result in a reduction in
disease transmission, detection of asymptomatic P. falci-
parum infection should be feasible, using a real time
and reliable diagnostic tool. In addition, the anti-malar-
ial therapy used should be effective against the transmis-
sible sexual stage of the parasite. In comparison with
non-artemisinin regimens, treatment with ACT, and in
particular with AL, has been shown to result in lower
gametocyte carriage rates and reduced infectivity of trea-
ted individuals [14,15]. The public health benefits of
ACT in reducing gametocyte carriage are noted in the
latest WHO Treatment Guidelines [9].
To explore the potential for the detection and treat-
ment of AC to reduce the disease burden within a regio-
nal area, a modelling and simulation analysis was
developed based on the published model by Okell et al.
[16]. This model, originally developed to explore the
impact of the introduction of ACT (after discontinua-
tion of sulphadoxine-pyrimethamine) on malaria ende-
micity in Tanzania, was modified to simulate the impact
of treating identified AC, and to explore the impact of
other factors that may influence the optimization of the
intervention.
This modelling and simulation analysis was designed
to evaluate the impact of an intervention defined as per-
iodic community screening campaigns (CSC) by RDT
followed by systematic treatment of AC with AL (Coar-
tem®) at the community level by showing a reduction in
the number of confirmed symptomatic malaria episodes
per person-year in the paediatric population (i.e. patients
< 5 years of age) and overall population over a 12-
month follow-up period, compared with no screening
and treatment. If the reduction is validated in a prospec-
tive clinical study, public health policymakers may want
to consider the potential of this intervention to make a
significant contribution to the multifaceted approach of
surveillance strategies being implemented by malaria
control programmes across Africa.
Methods
This modelling and simulation analysis utilised the basic
parasite model of malaria transmission in human and
mosquito populations published by Okell et al. [16].
This is a deterministic compartmental model that allows
subjects to move between different states. Subjects
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initially begin in a susceptible state and become infected
at a rate that is determined by mosquito density (m),
the human biting rate (b), the prevalence of infectious-
ness in the mosquito population (A), and the probability
of a subject developing a blood-stage infection. Subjects
advance to two latent states before being treated or left
untreated. For each of these latter two states, the model
progresses through four different levels that express the
degree of infectivity of the subject to mosquitoes. After
this fourth stage in either state, subjects recover and
return to the susceptible state. During each of the four
states for treated or untreated subjects, superinfection
can occur if the subject receives another infectious bite
(generally with a distinct parasite strain). The rate of
superinfection is set to be the same as the basic infec-
tion rate. The model was simulated using Matlab (Math-
works, Natick MA, USA). A simplified diagram of the
model is shown in Figure 1.
The subject population was divided into three groups:
children aged < 5 years, children aged 5-15 years, and
adolescents and adults > 15 years of age. Each of these
age groups had a biting rate value, scaled according to
the relative differences in body surface area and likeli-
hood of acquired immunity, both of which increase with
advancing age. The values used in the model for these
parameters were those given in the original model by
Okell et al. [16]. Additionally, there was heterogeneous
exposure of the population to infective bites, and the
model used the assumption that a small percentage of
the population in each of these age groups (10% per
group) received a large percentage of the mosquito bites
(80% of bites). This group is referred to as the high biting
intensity group. The remaining members of each group
were subject to biting of a lower intensity and are thus
referred to as the low biting intensity group (Figure 2).
A constant proportion of symptomatic subjects from
each age group was treated with ACT. The effectiveness
of AC detection (RDT effectiveness and population cov-
erage) and cure rate of the ACT are parameters in the
model. While the original model of Okell et al. [16]
explored the impact of presumptive treatment of symp-
tomatic individuals, for this analysis, the structure of the
model that simulated presumptive treatment was altered
to represent treatment following screening by RDT dur-
ing the time of a CSC. Outside the time of a CSC, this
portion of the model was disabled (dotted line in Figure
1). All simulated subjects progress through four states in
either the infectious or treated branches of the model.
The potential level of infectivity decreases as the sub-
jects progress through each state until they return to
the susceptible state again. Asymptomatic subjects who
were initially untreated but then received treatment
while in one of the four different infectivity states
moved to a corresponding treatment state appropriate
to the infectivity level. Additionally, the model of Okell
et al. [16] included a protective state for subjects
Figure 1 Schematic diagram of the human and vector model states (modified from Okell et al. 2008)[16].
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(prophylactic effect) prior to re-entering the susceptible
state. This state was excluded from the model to reflect
the relatively short half-life of AL as an ACT.
At the time of a CSC, AC were detected at a certain
effectiveness rate specified in the model and treated.
This only means that they were successfully diagnosed
and entered the ‘treated’ state of the model, in which
they could however still be subject to superinfection or
not respond to treatment. The number and timing of
the CSC can vary to assess different study designs. The
durations of the wet and dry seasons were modelled
using a sinusoidal function that alters the birth rate of
mosquitoes in a model of the vector dynamics. The
model assumes a six-month wet and dry season cycle
during the course of one year; variations in the duration
of each cycle were also tested (i.e. an eight-month wet
season or a four-month wet season). The vector model
also incorporated a susceptible state into which all the
mosquitoes begin. If they became infected via a bite,
they also entered a latent phase before progressing to an
infectious state. Mosquitoes die at a constant rate so
their density varies cyclically with the duration of the
wet and dry seasons.
The model parameters that were independent of the
different geographical region simulated by Okell et al.
were set to the same values used by those authors [16].
The remaining parameters that were dependent on
geographic region were adjusted to allow the dynamics
of infection without the CSC intervention (but with nor-
mal ACT treatment) to vary around a range of disease
prevalence rates. These included the three parameters
that impact the disease intensity: mosquito density (m),
the human biting rate (b), and the prevalence of infec-
tiousness in the mosquito population (A).
Simulations were assessed with normal treatment of
symptomatic malaria episodes with AL but without
CSCs, to establish baseline levels of malaria incidence
within a restricted population. It was assumed that there
was low (< 10%) loss or cross-contamination of subjects
from one village or region to another region. To assess
the impact of the intervention, the model ran for a
simulated time of two consecutive years without any
intervention to allow the steady state condition to
develop. The intervention with the series of CSCs was
then started at the commencement of the dry season of
Year 3.
The impact of different numbers of CSCs and the
intervals between them on the simulated incidence of
malaria, up to and including the complete year following
the intervention, were assessed to determine the optimal
placement of CSC so that the subsequent predicted inci-
dence of malaria was minimized. As a quantitative indi-
cator of the simulated intervention, the area under the
curve (AUC) for the percentage of patients without
Figure 2 Schematic of the population distribution based on age and propensity to receive mosquito bites. Following the model of Okell
et al. (2008)[16], there is heterogeneous exposure of the population to infective bites.
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malaria within the target age group of interest - in this
analysis, children under five years of age - was calcu-
lated to assess the impact of the intervention in both
the year of implementation and the subsequent year.
The impacts of CSC total number, frequency and rela-
tive timing were assessed to determine the greatest
impact on reducing malaria incidence within the target
age group. A sensitivity analysis was also conducted to
determine the influence of mosquito density, ACT cure
rate, and the percentage of symptomatic infected inhabi-
tants in the population on the model predictions.
Results
Normal cyclic patterns of malaria transmission were
modelled for a range of transmission intensities, which
are dependent on mosquito density and other infectivity
parameters (mosquito infectiousness, human biting rate,
probability that an infectious bite develops into a blood
stage infection). Figure 3 shows the range of malaria
incidence (asymptomatic and symptomatic) that would
be expected to occur in a given region as a function of
the mosquito density parameter. With an increasing
number of mosquitoes, the number of susceptible sub-
jects drops as more of the population contracts malaria.
The relationship between mosquito density (m) and the
entomological inoculation rate (EIR), which is com-
monly expressed in different malaria regions, was
assessed on the basis of the model output of malaria
incidence in the population. A mosquito density value
of 1.25 would approximate a region of moderate ende-
micity (EIR < 100). A density value of 5 would approxi-
mate a highly endemic region (EIR > 200) that still
possesses seasonality in the malaria incidence.
A sensitivity analysis was conducted to assess the
impact of model parameters on the predicted incidence
of malaria within the target population. As shown in
Figures 4 and 5, the impact of the treatment cure rate
(the percentage of subjects cured with a standard course
of AL therapy) and the percentage of inhabitants with
symptomatic malaria within a population both had pro-
portional impact on the overall rate of malaria incidence
within each age group. Each model parameter was
allowed to vary over a range of values to assess which
had the largest effect on the model predictions. As
anticipated, the parameters that had the greatest impact
on the model predictions were the factors that directly
influenced malaria exposure (mosquito density [m], the
human biting rate [b], or the prevalence of infectious-
ness in the mosquito population [A]). All other model
parameters had only a modest effect on the predicted
Figure 3 Simulated steady state conditions that show the
change in malaria incidence with the change in mosquito
density within the target population of children aged < 5 years
old at the end of the rainy season or the end of the dry
season. With increasing mosquito density, more subjects have
malaria for longer parts of the year. At the end of the rainy season,
the lowest percentage of subjects is malaria-free.
Figure 4 Sensitivity analysis of the impact of ACT cure rate on
the steady state malaria levels at the end of a dry or rainy
season. With increasing cure rate estimates, the number of subjects
without malaria at the end of either season increases.
Figure 5 Influence of the percentage of symptomatic subjects
who have malaria on the underlying disease levels. As more
subjects are symptomatic, more are able to be treated resulting in
less patients with malaria at the end of either the dry or rainy
season.
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percentage of patients with malaria in either the target
or the whole population.
Conducting the entire series of CSC during the dry
season and the interval between each campaign both
had a large impact on the overall strategy success. The
strongest decrease in malaria incidence in the target
population, as indicated by the AUC for the malaria
incidence, was observed with a total of three CSCs
placed in close succession (separated by one month
each for three months). When the CSCs were placed
three months apart, at months 1, 3 and 6 of the dry sea-
son (i.e. start, middle, and end of the dry season), the
effectiveness of the intervention was decreased and the
subsequent impact on the next malaria season was
reduced (Figure 6). CSC at months 1, 2, and 3 or at
months 1, 2 and 4 of a 6-month dry season essentially
showed the same overall response for reducing malaria
in the following rainy season and the subsequent dry
season. The addition of an extra CSC in the wet season,
e.g. around the peak of transmission, did not markedly
improve the success of the overall intervention. The use
of a single CSC showed the least sustainable results and
represents a strategy that is not likely to have a sustain-
able effect.
As the intensity of transmission increased, the
decrease in malaria incidence within the year of inter-
vention was still observed, but the carry-over of that
reduction into subsequent years after the intervention
was reduced. Thus, the sustainability of the intervention
is directly related to transmission intensity in the area.
Figure 7 shows that the greatest overall impact of the
intervention was seen when it was implemented in an
area where intensity of transmission was moderate (i.e.
equivalent to EIR < 100). The results show that while
malaria was reduced significantly in an area with the
higher transmission intensity during the analysis year,
the rate of infection returned to normal cyclic fluctua-
tions in the immediate ensuing year, unless the inter-
vention was repeated. Conversely, as the intensity of
transmission decreased (Figure 7; M = 0.5; green curve),
the impact on malaria in the region carried over for at
least two years after that of the intervention. The impact
of the best overall CSC strategy on an area with a low
disease prevalence lasted for > 3 years after the treat-
ment ended. This result indicates that in regions where
other interventions have already reduced the malaria
burden, this strategy may be an important additional
factor for eliminating the remaining malaria cases within
a region.
Discussion
The results of this simulation analysis show that strate-
gically placed community screening campaigns that are
effective at treating AC of malaria will have a significant
impact on reducing the disease incidence in the most
vulnerable population, i.e. children below five years of
age. While this population was the focus of assessment
in this simulation analysis, the results showed that
Figure 6 Impact of the study treatment on parasite prevalence
within a population, with moderate transmission intensity (M
= 1.25, EIR < 100) and CSC scheduled at months 1, 2 and 3 or
months 1, 3 and 6 of the dry season. The panel shows the
percentage of children < 5 years of age who are parasite free in the
high-biting group. By repeatedly screening the population and
treating the asymptomatic carriers at short time intervals, the rate of
parasite prevalence can be reduced for two consecutive years as
determined by the area under the curve for each year.
Figure 7 The comparison of transmission intensity on
treatment success with CSC spaced one month apart for three
months. At some level of transmission intensity (i.e. M = 5, EIR >
200), the parasite burden is too great so that eradication is not
sustained within the population, indicated by the area under the
curve of the malaria incidence. When the transmission intensity is
low (i.e. M = 0.5, EIR < 10), the parasite burden is low and
eradication is sustained within the population for at least 2 years
after the intervention. This highlights the need for this strategy to
be coupled with other interventions, when used in areas of
moderate transmission intensity (i.e. M = 1.25, EIR < 100).
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the incidence of malaria was reduced in the total
population.
The model sensitivity analysis showed that both the
efficacy of the ACT used and the percentage of AC trea-
ted had a direct linear relationship with the success of
the intervention, as reflected in the minimum and maxi-
mum number of subjects without malaria within a popu-
lation for a subsequent year. Thus, it is important that a
highly effective therapeutic agent is used and treatment
of as close to 100% of AC as possible is achieved, in
order for this strategy to be effective when it is actually
implemented. It is also important to have an accurate
and sensitive means to detect malaria in asymptomatic
patients to have a maximal impact. A conservative rate of
detection and treatment of AC of 80% was chosen in this
analysis. This percentage was felt to be a reasonable esti-
mate for an aggressive screening campaign, and would
take into account those subjects who might be away
from their region during the timing of any of the CSC or
who enter the region after cessation of the intervention
(e.g. due to school attendance elsewhere, work in another
region, or migration). The percentage is similar to that
found by von Seidlein et al [17] in their study of mass
drug administration to reduce malaria transmission in
The Gambia. In this simulation, a conservative estimate
was used for therapeutic agent efficacy of 90%, a slightly
lower cure rate for AL than the > 95% efficacy typically
reported in many clinical trials [18-22].
The mosquito density within a region was the factor
that had the greatest impact on the success of the inter-
vention. The lower the endemicity within a region with
seasonality, the longer the effect of a single-intervention
implementation would persist. At the lowest endemicity,
the effect was maintained for up to five years after the
implementation, as predicted by Lawpoolsri [23] in the
low endemicity Thai-Myanmar border region. As the
mosquito density and EIR increased in a simulated area,
the ability of the intervention to reduce malaria inci-
dence beyond the year of treatment tapered off. In order
for the impact of the strategy to be sustained in a
highly-endemic region, it would be best implemented as
part of a strategy of combined interventions, and the
intervention should be repeated with some frequency
depending on the level of successful reduction achieved
with other complementary approaches. This suggests
that combining this approach with other effective strate-
gies, such as LLIN universal coverage, indoor residual
spraying, prompt diagnosis and effective case manage-
ment, could be an important factor in achieving the goal
of malaria elimination in appropriate regions.
The effect of the timing of the multiple CSC was an
interesting factor that emerged from the simulation ana-
lysis. By clustering the campaigns earlier in the dry sea-
son and in relatively quick succession, the incidence of
malaria in the transmission season after intervention
was more effectively reduced. This is likely due to the
latency period between an infectious bite and the devel-
opment of blood stage parasitaemia. By rapidly repeating
the CSC, subjects who were not detected in the initial
campaign could be detected in the subsequent campaign
and immediately treated. This prevents the disease from
developing to its full stage of progression; a full cycle in
the model generally takes almost 6 months to complete
and return to the susceptible state again. The disease
progression was modelled using ordinary differential
equations that did not account for the potential to have
stochastic bursts of malaria within a region or subgroup
of patients. If such features of the disease were to
appear, particularly in the post-intervention assessment
period, it could influence the estimated success of the
intervention in a region.
In the study by von Seidlein et al. in The Gambia [17],
there was only a single treatment campaign of 85% of
the population without prior screening. The treatment
campaign used artesunate-sulphadoxine-pyrimethamine,
a therapeutic agent that had lower reported efficacy
than AL for clearing mature gametocytes in asympto-
matic subjects. In addition, a number of villages from
the treated group and the placebo group were often
only 2 km apart. Consequently, it is unlikely that the
‘treated’ and ‘control’ human and vector populations
were clearly separated from one another. All these fac-
tors may have contributed to the lack of effect on
malaria incidence found in this study, as confirmed in a
simulation of this study approach with the model pre-
sented here. Figure 8 shows a good representation of
Figure 8 Model prediction calibration simulating a single CSC
held at the start of the dry season. This approach is
representative of the study by von Seidlein et al in The Gambia
where a single mass screening campaign was undertaken in a high
intensity region. As the study showed, the impact was not sustained
and resulted in higher susceptibility for a short time immediately
after the intervention (irrespective of the group considered, high or
low-biting intensity).
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the outcome of von Seidlein [17], which emphasizes the
importance of active screening in multiple successive
CSC. The von Seidlein et al. study was also undertaken
in a highly endemic region prior to the widespread utili-
zation of other interventions such as LLIN. As the pre-
sent simulation analysis shows, the relative level of
disease intensity has a large impact on how successful a
single treatment cycle of asymptomatic patients is likely
to be. Reducing the pool of infectious vectors in this
population is only a partial step in disease eradication if
it is not combined with other effective strategies.
The results of this study complement the recent publi-
cation by Griffin et al. [24] that also used the Okell
model to evaluate malaria intervention strategies across
different malaria transmission settings found in Africa.
Griffin and colleagues found that with increasing trans-
mission intensity, reflected by a higher EIR, combina-
tions of intervention are necessary to reduce malaria
transmission levels significantly. For regions with mod-
erate and high transmission intensity, systematic screen-
ing and treatment paradigms would reduce parasite
prevalence in a region, but would have to be repeated
for sustained effect. In a complementary manner, the
results provide an estimate of the frequency and charac-
teristics of this type of intervention that would be neces-
sary for sustaining transmission reduction.
The addition of seasonality to the Okell model allows
for the assessment of the dynamics of malaria transmis-
sion. The extended period of time between when a sub-
ject is first infected and exhibits clinical symptoms adds
to the complexity of treating this disease. Taking a sys-
tems engineering viewpoint to the question of when to
best place the CSCs to control disease spread, it
becomes apparent that the placement and interval
between the campaigns has to harmonize with the nat-
ural frequency of the disease spread. In this regard, stra-
tegically placed CSC should complement other
interventions, such as IPT in pregnancy, the deployment
of LLINs and programmes of indoor residual spraying.
Conclusions
In conclusion, this simulation analysis identified condi-
tions that may contribute to the successful implementa-
tion of an intervention to reduce the pool of infectious
vectors for malaria transmission by treating AC of P.
falciparum. By doing so in a region with marked seaso-
nal transmission and a moderate malaria incidence such
as the Sahelian zone (Senegal, Mali, Burkina Faso), and
by combining this with other successful interventions,
there is an opportunity to reduce malaria transmission,
particularly in those most at risk. It is likely that com-
bining this approach with already existing methods for
vector control will have a more lasting impact, particu-
larly in regions with high disease incidence.
This simulation analysis highlights the utility of rela-
tively simple models of malaria disease dynamics and
therapeutic impact that may be important for planning
a potentially complicated and resource-intense clinical
study to further explore this treatment strategy. The
benefit of malaria modelling was noted in a perspective
article published in parallel with the original Okell mod-
elling paper [25]. This article concludes that mathemati-
cal modelling may help to preserve the efficacy of
currently available ACT, monitor for the emergence of
resistance, and contribute to malaria control. The
approach described in this analysis should allow an
upcoming clinical trial in Burkina Faso to prospectively
assess the potential for the treatment of AC to make a
contribution to the multifaceted approaches currently
being utilized across Africa. As malaria elimination
becomes a realistic probability in certain epidemiological
settings, the treatment of AC could work in conjunction
with existing interventions such as prompt diagnosis by
RDT and effective case management, IPT, and vector
control to build upon the achievements of the past 10
years. The results of this simulation support the testing
of the hypothesis in a clinical study to assess its validity.
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